Your browser doesn't support javascript.
loading
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt, Hartmut; Mai, Elias K; Bertsch, Uta; Fenk, Roland; Nievergall, Eva; Tichy, Diana; Besemer, Britta; Dürig, Jan; Schroers, Roland; von Metzler, Ivana; Hänel, Mathias; Mann, Christoph; Asemissen, Anne M; Heilmeier, Bernhard; Weinhold, Niels; Huhn, Stefanie; Kriegsmann, Katharina; Luntz, Steffen P; Holderried, Tobias A W; Trautmann-Grill, Karolin; Gezer, Deniz; Klaiber-Hakimi, Maika; Müller, Martin; Khandanpour, Cyrus; Knauf, Wolfgang; Scheid, Christof; Munder, Markus; Geer, Thomas; Riesenberg, Hendrik; Thomalla, Jörg; Hoffmann, Martin; Raab, Marc S; Salwender, Hans J; Weisel, Katja C.
Affiliation
  • Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany. Electronic address: hartmut.goldschmidt@med.uni-heidelberg.de.
  • Mai EK; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Bertsch U; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Fenk R; Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
  • Nievergall E; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Tichy D; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.
  • Besemer B; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
  • Dürig J; Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
  • Schroers R; Medical Clinical, University Hospital Bochum, Bochum, Germany.
  • von Metzler I; Department of Medicine, Hematology, and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
  • Hänel M; Department of Internal Medicine III, Clinic Chemnitz, Chemnitz, Germany.
  • Mann C; Department for Hematology, Oncology, and Immunology, University Hospital of Gießen and Marburg, Marburg, Germany.
  • Asemissen AM; Department of Oncology, Hematology and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Heilmeier B; Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany.
  • Weinhold N; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Huhn S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Kriegsmann K; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Luntz SP; Coordination Centre for Clinical Trials Heidelberg, Heidelberg, Germany.
  • Holderried TAW; Department of Oncology, Hematology, ImmunoOncology, and Rheumatology, University Hospital Bonn, Bonn, Germany.
  • Trautmann-Grill K; Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany.
  • Gezer D; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
  • Klaiber-Hakimi M; Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.
  • Müller M; Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Hannover, Germany.
  • Khandanpour C; Medical Clinic A, University Hospital Münster, Münster, Germany.
  • Knauf W; Center for Hematology and Oncology Bethanien, Frankfurt, Germany.
  • Scheid C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
  • Munder M; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany.
  • Geer T; Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany.
  • Riesenberg H; Hematology and Oncology Center, Bielefeld, Germany.
  • Thomalla J; Hematology and Oncology Center, Koblenz, Germany.
  • Hoffmann M; Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany.
  • Raab MS; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona, AK St Georg, Hamburg, Germany.
  • Weisel KC; Department of Oncology, Hematology and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Lancet Haematol ; 9(11): e810-e821, 2022 Nov.
Article in En | MEDLINE | ID: mdl-36328040
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2022 Type: Article